Please wait...

Learn

Finding accredited CPD

Semaglutide 2.4 mg in obesity and prediabetes - Obesity Watch 1

Description

The Watch series will introduce a regular video series of educational topics presented by Australian specialists and capturing the flavour of local practice. The first in this series is a discussion by Dr Ramy H Bishay, an Endocrinologist from Sydney, titled: Semaglutide 2.4 mg in obesity and prediabetes.


Details

Presented by Dr Ramy H Bishay MSc, MBBS, FRACP

This activity is accepted by CPD Home as a Domain 1: Educational Activity in alignment with the CPD Home Program Guide.

Disclaimer: Please note, once you click 'Enrol now' you will be leaving the AMA’s CPD Home website and entering a third-party website. 

Provided by


CPD Activity Details
Topic
General Practice and Primary Care, Endocrine System Diseases, Nutritional and Metabolic Diseases
CAPE Aspects
_
Effective Year

Educational Activities (EA) - 0.15

Reviewing Performance (RP) - 0.0

Measuring Outcomes (MO) - 0.0

You have to log in to see the content of this module.

*Medical Board of Australia’s (MBA)’s revised Registration Standard: Continuing professional development (the Standard)